Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)
Trial Parameters
Brief Summary
This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.
Eligibility Criteria
Inclusion Criteria: 1. Stable recurrent chest pain. 2. 40 to 75 years old. 3. Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\<50% coronary artery stenosis or fractional flow reserve \>0.8). 4. Stress CMR MPR \<2.19 12 or Stress MBF \<2.19ml/g/min 13. 5. Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention. Exclusion Criteria: 1. Systolic blood pressure \<100 mm Hg. 2. Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil). 3. Has known allergy or sensitivity to any soluble guanylate cyclase stimulator. 4. On long-acting nitrates (eg. isosorbide mono